Braun, David A. http://orcid.org/0000-0003-4543-5553
Bakouny, Ziad
Hirsch, Laure
Flippot, Ronan
Van Allen, Eliezer M.
Wu, Catherine J.
Choueiri, Toni K. http://orcid.org/0000-0002-9201-3217
Article History
Accepted: 16 November 2020
First Online: 12 January 2021
Competing interests
: D.A.B. has acted as a consultant of Adept Field Solutions, Blueprint Partnerships, Charles River Associates, Dedham Group, Defined Health, Insight Strategy, Octane Global, Slingshot Insights and Trinity Group, has received travel support from Bristol Myers Squibb and has received honoraria from LM Education/Exchange Services. Z.B. has received research support from Bristol Myers Squibb and Genentech. E.M.V.A. has served on the advisory boards of Enara Bio, Genome Medical, Manifold Bio, and Monte Rosa, has acted as a consultant of Invitae, Janssen and Tango Therapeutics, has received research funding from Bristol Myers Squibb-IION and Novartis, holds equity in Enara Bio, Genome Medical, Manifold Bio, Microsoft, Monte Rosa, Syapse and Tango Therapeutics, has received travel support from Roche/Genentech, and is listed on several institutional patents filed on chromatin mutations and immunotherapy response, and methods for clinical interpretation. C.J.W. holds equity in BioNtech. T.K.C. has acted as a consultant of AstraZeneca, Bristol Myers Squibb, Corvus, Eisai, Exelixis, Genentech, GlaxoSmithKline, Ipsen, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Roche, Surface Oncology, Tracon and Up-to-Date, and has received research funding from Astellas, AstraZeneca, Bristol Myers Squibb, Corvus, Exelixis, Genentech, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer and Tracon. The other authors declare no competing interests.